Schematic representation of the prevalence of monoclonal gammopathies according to the classical view (above) and to the most recent findings (below). The iStopMM population screening study on Icelandic adults used serum protein electrophoresis and free light chain measurement.5 The PROMISE screening study on high-risk populations used mass spectrometry.6 Genomics cohort-based studies estimated the timing of initiation of clonal plasma cell conditions.1,2,4 The size and proportion of the figure are not in scale and are only meant to support a conceptual view of prevalence of the conditions. MGUS, monoclonal gammopathy of unknown significance; MM, multiple myeloma; SMM, smoldering multiple myeloma. Professional illustration by Patrick Lane, ScEYEnce Studios.
